| 000 | 01635 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250513190556.0 | ||
| 264 | 0 | _c19990921 | |
| 008 | 199909s 0 0 eng d | ||
| 022 | _a1043-4666 | ||
| 024 | 7 |
_a10.1006/cyto.1998.0462 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLibert, C | |
| 245 | 0 | 0 |
_aThe role of complement activation in tumour necrosis factor-induced lethal hepatitis. _h[electronic resource] |
| 260 |
_bCytokine _cAug 1999 |
||
| 300 |
_a617-25 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aChemical and Drug Induced Liver Injury _ximmunology |
| 650 | 0 | 4 |
_aComplement Activation _xdrug effects |
| 650 | 0 | 4 |
_aComplement C1q _xanalysis |
| 650 | 0 | 4 |
_aComplement C3b _xanalysis |
| 650 | 0 | 4 |
_aComplement Pathway, Alternative _ximmunology |
| 650 | 0 | 4 |
_aComplement Pathway, Classical _ximmunology |
| 650 | 0 | 4 |
_aElapid Venoms _xpharmacology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGalactosamine _xtoxicity |
| 650 | 0 | 4 |
_aLiver _xdrug effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMice, Inbred BALB C |
| 650 | 0 | 4 | _aMice, Inbred C57BL |
| 650 | 0 | 4 | _aMice, Inbred CBA |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xtoxicity |
| 700 | 1 | _aWielockx, B | |
| 700 | 1 | _aGrijalba, B | |
| 700 | 1 | _aVan Molle, W | |
| 700 | 1 | _aKremmer, E | |
| 700 | 1 | _aColten, H R | |
| 700 | 1 | _aFiers, W | |
| 700 | 1 | _aBrouckaert, P | |
| 773 | 0 |
_tCytokine _gvol. 11 _gno. 8 _gp. 617-25 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1006/cyto.1998.0462 _zAvailable from publisher's website |
| 999 |
_c10391589 _d10391589 |
||